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We have been told for several years now that all human tumors are the result of genetic aberrations leading to a progressive malfunctioning of the cell machinery and that the more the aberrations, the greater the cell malfunctioning. As a matter of fact, this has become the overriding dogma of oncology, to the point of prompting the Head of the National Cancer Institute to challenge researchers in the field to produce a molecular classification of tumors that will better reflect their biological properties and replace the tired morphologic schemes that have been laboriously laid down during the course of the last century.
While accepting the possibility of this dream eventually becoming a reality, one cannot fail to appreciate how naive some of the first attempts in this direction have been and how preposterous some of the claims appear. A prime example is provided by the group of solid tumors associated with consistent chromosomal aberrations, such as pediatric and adults soft tissue tumors, renal carcinomas, and thyroid carcinomas. Whenever a nonrandom chromosomal aberration is uncovered, the impression is generated that the existence of that tumor as an entity has finally been scientifically validated and-most significantly-that the pathogenesis of that tumor has been unraveled.
What I mean by the latter is that the description of the karyotypic change is often accompanied by the implicit or stated statement that the chromosomal alteration in question is 'necessary" and "sufficient" to generate that tumor. In plain words, the tumor has developed because of that alteration, just as tuberculosis has developed because of the Koch bacillus, everything else being a modifier or an epiphenomenon. To quote as an example the tumor type to which this Editorial is ultimately directed, the statement has been made that "papillary thyroid carcinomas appear to arise is one genetic step," the step in question in this case being the molecular event leading to the formation of the RET/PTC oncogene [1] . It is very hard to believe that this is the case. These are the reasons why:
1. If, let's say, the SYT-SSX gene fusion is "necessary" to generate the soft tissue tumor which we call synovial sarcoma, it becomes difficult to visualize the existence of a tumor that lacks that particular gene fusion-for instance, a fibrosarcoma, a leiomyosarcoma, or a malignant peripheral nerve sheath tumor-but that is still endowed with all of the biological properties of a synovial sarcoma, from which it differs only because of some inconsequential morphologic traits (which, as every pathologist knows, can be very subtle).
2. It seems inconceivable that the intricate and devilishly effcient machinery of a tumor cell could spring forth merely by the action of the few proteins generated by the gene fusion in question.
3. If a genetic alteration were "sufficient" to cause the tumor it has been found to be associated with, it follows that any cell having that alteration is a tumor cell and-as a corollary-a representative of that tumor type. The article by Sheils et al in this issue of the Journal strongly suggests that this is not so, in that it demonstrates that in 15 of 16 thyroid glands affected by Hashimoto thyroiditis, but lacking morphologic evidence of papillary carcinoma, had molecular evidence for the presence of the RET/PTC oncogene. It thus provides a rotund confirmation of the findings reported in 1997 by Wirtschafter et al. [2] , which until now have been carefully ignored by most workers in the field. Those authors tried to explain their remarkable finding by postulating that all of their thyroid glands with Hashimoto thyroiditis had a papillary carcinoma, even if that was inapparent on microscopic examination. The explanation given by Sheils et al in this issue seems much more credible. They accept the possibility that the RET/PTC alteration may be directly responsible for the peculiar nuclear changes seen in both Hashimoto thyroiditis and papillary carcinoma-a notion already postulated by Fischer et al. [1] on the basis of their elegant experimentand perhaps even for the lymphoid infiltration of the gland, but they imply that more, much more, is needed to produce a full blown papillary carcinoma.
Actually, one wonders whether this may not be viewed as a general theme in oncology, i.e., that the various molecular alterations that have been detected in solid tumors are more closely related to given morphologic traits than to the fundamental biologic properties of the cancer cell. As an example, the association between SYT-SSX with the synovial sarcoma phenotype and its morphologic subtypes (biphasic and monophasic) is impressive and thoroughly convincing, certainly more so than the claims made of an association between those molecular alterations and the clinical outcome [3, 4] . Historically, tumor biologists have paid relatively little attention to the fine morphologic differences that exist among tumors, believing that the property to invade locally, to permeate lymph and blood vessels, and to colonize distantly mattered much more than whether the tumor looked like a fibrosarcoma, a myxofibrosarcoma, or a leiomyosarcoma. Following that line of thought, if one were to find that the main consequence of the various translocations that have been described in solid tumors is simply to induce a certain set of morphologic features, one might as well conclude that the ultimate explanation for the acquisition of the fundamental biological properties that make a cell a cancer cell, regardless of its microscopic subtype, still remains a mystery. I, for one, find appealing the idea that the latter is related to the derepression of a set of elabo-rate programs that exist in the parent cell in a latent or silent state and that probably played an important and perhaps vital role during phylogenetic and ontogenetic evolution. But let's not get carried away, lest we forget the important conclusion derived by the work of by Sheils et al.: RET/PTC alone does not a papillary thyroid carcinoma make.
